

April 14, 2008



Hercules Technology Announces Bankruptcy Court Approval of Plan for Repayment of Outstanding Loan from Diomed Holdings, Inc.

PALO ALTO, Calif.--(BUSINESS WIRE)--

Hercules Technology Growth Capital, Inc. (NASDAQ: HTGC), the premier specialty finance company providing venture debt and equity to venture capital and private equity backed technology and life science companies at all stages of development, today announced that it will receive repayment of principal on the company's debt financing to Diomed Holdings, Inc. (AMEX: DIO), which is currently in Chapter 11 reorganization.

Diomed recently announced it has entered into a settlement agreement with AngioDynamics, Inc. (NASDAQ: ANGO), for the purpose of resolving the patent infringement lawsuit between the companies originally filed in January 2004. As a result of the settlement over varicose vein laser treatment technology, AngioDynamics agreed to pay \$7.0 million to Diomed. Of the \$7.0 million settlement proceeds, \$6.0 million will be used to repay the outstanding loan principal balance to Hercules per a settlement order approved by the United States Court of Bankruptcy for the District of Massachusetts.

"Our anticipated repayment of our outstanding loan from Diomed demonstrates Hercules' ability to minimize risks to our investors, even amid distressed situations," said Manuel A. Henriquez, co-founder, chairman and chief executive officer of Hercules.

Additionally, Vascular Solutions, Inc. (NASDAQ: VASC), announced on April 9, 2008, that it has entered into a separate settlement agreement with Diomed for the purpose of resolving the patent infringement lawsuit between the companies. Pursuant to the settlement agreement, all claims and appeals by each side will be dismissed following a one-time payment of \$3.586 million from Vascular Solutions to Diomed.

About Hercules Technology Growth Capital, Inc.:

Hercules Technology Growth Capital, Inc. is a NASDAQ traded specialty finance company providing debt and equity growth capital to technology and life science companies at all stages of development. Founded in December 2003, the company primarily finances privately held companies backed by leading venture capital and private equity firms. Hercules invests in a broad range of ventures active in technology and life science industries and offers a full suite of growth capital products up and down the capital structure. The company is headquartered in Palo Alto, Calif. and has additional offices in the Boston, Boulder, San Diego and Chicago areas. Providing capital to publicly-traded or privately-held companies backed by leading venture capital and private equity firms involves a high degree

of credit risk and may result in potential losses of capital. For more information, please visit www.HTGC.com.

Companies interested in learning more about financing opportunities should contact info@HTGC.com, or call 650.289.3060.

Forward-Looking Statements:

The statements contained in this release that are not purely historical are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties and other factors we identify from time to time in our filings with the Securities and Exchange Commission. Although we believe that the assumptions on which these forward-looking statements are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Hercules assumes no obligation to update the forward-looking statements for subsequent events.

Source: Hercules Technology Growth Capital, Inc.